Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world study

https://doi.org/10.1101/2020.10.30.20215301

The purpose of this study was to evaluate the effectiveness and safety of RDV in patients with COVID-19 in real world settings. Patients were selected from 1496 individuals included in the SARSTer national
database; 122 of them received therapy with RDV and 211 were treated with lopinavir/ritonavir (LPV/r)-based therapy. Significantly higher rates of clinical improvement, by 15% and 10% respectively, were observed after RDV treatment compared to LPV/r at days 21 and 28. The difference
between regimens increased with worsening of oxygen saturation (SpO2) and depending on the baseline score from the ordinal scale. Statistically significant differences supporting RDV were also noted regarding the rate of no clinical improvement within 28 days of hospitalization and hospitalization duration in patients with baseline SpO2 ≤90% In conclusion, data collected in this retrospective, observational, real world study supported use of remdesivir for treatment of SARS-CoV-2 infection particularly in patients with oxygen saturation ≤95%.

Tags: